• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见遗传病临床试验中招募和留住参与者的实际问题:苯丙酮尿症(PKU)的经验

Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience.

作者信息

DeWard Stephanie J, Wilson Ashley, Bausell Heather, Volz Ashley S, Mooney Kimberly

机构信息

Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, 4401 Penn Ave., Pittsburgh, PA, 15224, USA,

出版信息

J Genet Couns. 2014 Feb;23(1):20-8. doi: 10.1007/s10897-013-9642-y. Epub 2013 Sep 8.

DOI:10.1007/s10897-013-9642-y
PMID:24014152
Abstract

Bringing treatments for rare genetic diseases to patients requires clinical research. Despite increasing activism from patient support and advocacy groups to increase access to clinical research studies, connecting rare disease patients with the clinical research opportunities that may help them has proven challenging. Chief among these challenges are the low incidence of these diseases resulting in a very small pool of known patients with a particular disease, difficulty of diagnosing rare genetic diseases, logistical issues such as long distances to the nearest treatment center, and substantial disease burden leading to loss of independence. Using clinical studies of phenylketonuria as an example, this paper discusses how, based on the authors' collective experience, partnership among clinicians, patients, study coordinators, genetic counselors, dietitians, industry, patient support groups, and families can help overcome the challenges of recruiting and retaining patients in rare disease clinical trials. We discuss specific methods of collaboration, communication, and education as part of a long-term effort to build a community committed to advancing the medical care of patients with rare genetic diseases. By talking to patients and families regularly about research initiatives and taking steps to make study participation as easy as possible, rare disease clinic staff can help ensure adequate study enrollment and successful study completion.

摘要

为罕见遗传病患者提供治疗需要进行临床研究。尽管患者支持和倡导团体越来越积极地行动,以增加患者参与临床研究的机会,但事实证明,将罕见病患者与可能对他们有帮助的临床研究机会联系起来颇具挑战性。这些挑战中最主要的是这些疾病发病率低,导致已知患有特定疾病的患者群体非常小;罕见遗传病诊断困难;后勤问题,如到最近治疗中心的距离很远;以及疾病负担过重导致患者失去独立能力。本文以苯丙酮尿症的临床研究为例,基于作者的共同经验,探讨临床医生、患者、研究协调员、遗传咨询师、营养师、企业、患者支持团体和家庭之间的合作如何有助于克服罕见病临床试验中招募和留住患者的挑战。我们讨论了作为长期努力的一部分的具体合作、沟通和教育方法,以建立一个致力于推进罕见遗传病患者医疗护理的社区。通过定期与患者和家庭交流研究计划,并采取措施使参与研究尽可能轻松,罕见病诊所的工作人员可以帮助确保有足够的研究入组人数并成功完成研究。

相似文献

1
Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience.罕见遗传病临床试验中招募和留住参与者的实际问题:苯丙酮尿症(PKU)的经验
J Genet Couns. 2014 Feb;23(1):20-8. doi: 10.1007/s10897-013-9642-y. Epub 2013 Sep 8.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders.新生儿筛查连接系统(NBS connect)的开发:一个自我报告的患者登记系统及其在改善遗传性代谢疾病患者护理方面的作用。
Orphanet J Rare Dis. 2017 Jul 19;12(1):132. doi: 10.1186/s13023-017-0684-3.
4
National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.美国国立卫生研究院共识发展会议声明:苯丙酮尿症——筛查与管理,2000年10月16 - 18日
Pediatrics. 2001 Oct;108(4):972-82. doi: 10.1542/peds.108.4.972.
5
Phenylketonuria (PKU): screening and management.苯丙酮尿症(PKU):筛查与管理
NIH Consens Statement. 2000;17(3):1-33.
6
Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study.中国苯丙酮尿症的家庭经济负担及其对治疗的影响:一项横断面研究
J Inherit Metab Dis. 2017 May;40(3):369-376. doi: 10.1007/s10545-016-9995-0. Epub 2016 Nov 10.
7
A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment.一种在社区环境中开展临床试验的新方法:利用患者驱动的平台和社交媒体来推动基于网络的患者招募。
BMC Med Res Methodol. 2020 Mar 13;20(1):58. doi: 10.1186/s12874-020-00926-y.
8
Adult patient perspectives on phenylketonuria care: Highlighting the need for dedicated adult management and services.成年苯丙酮尿症患者对治疗的看法:强调成人专属管理和服务的必要性。
Eur J Med Genet. 2020 Apr;63(4):103818. doi: 10.1016/j.ejmg.2019.103818. Epub 2019 Nov 25.
9
Up to date knowledge on different treatment strategies for phenylketonuria.关于苯丙酮尿症不同治疗策略的最新知识。
Mol Genet Metab. 2011;104 Suppl(0):S19-25. doi: 10.1016/j.ymgme.2011.08.009. Epub 2011 Aug 16.
10
Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.早期治疗苯丙酮尿症患者的心理健康和社会功能:PKU-COBESO 研究。
Mol Genet Metab. 2013;110 Suppl:S57-61. doi: 10.1016/j.ymgme.2013.10.011. Epub 2013 Oct 22.

引用本文的文献

1
Clinical research in rare diseases in Brazil: challenges and opportunities.巴西罕见病的临床研究:挑战与机遇。
J Community Genet. 2025 May 15. doi: 10.1007/s12687-025-00793-4.
2
Body Composition Evaluation and Clinical Markers of Cardiometabolic Risk in Patients with Phenylketonuria.苯丙酮尿症患者的身体成分评估和心血管代谢风险的临床标志物。
Nutrients. 2023 Dec 18;15(24):5133. doi: 10.3390/nu15245133.
3
What role can decentralized trial designs play to improve rare disease studies?去中心化试验设计在改善罕见病研究方面可以发挥什么作用?

本文引用的文献

1
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.囊性纤维化跨膜电导调节因子增效剂治疗囊性纤维化跨膜电导调节因子 G551D 突变患者。
N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
2
Spontaneous coronary artery dissection: a disease-specific, social networking community-initiated study.自发性冠状动脉夹层:一项基于疾病特异性、社交网络社区发起的研究。
Mayo Clin Proc. 2011 Sep;86(9):845-50. doi: 10.4065/mcp.2011.0312.
3
Improving subject recruitment, retention, and participation in research through Peplau's theory of interpersonal relations.
Orphanet J Rare Dis. 2022 Jun 20;17(1):240. doi: 10.1186/s13023-022-02388-5.
4
Challenges Faced by Behavioral Genetic Studies: Researchers Perspective from the MENA Region.行为遗传学研究面临的挑战:中东和北非地区研究者的视角
Curr Genomics. 2021 Dec 31;22(7):550-556. doi: 10.2174/1389202923666211216162141.
5
A Roadmap to Patient Engagement: Facioscapulohumeral Muscular Dystrophy and the ReSolve Clinical Trial.患者参与路线图:面肩肱型肌营养不良症与ReSolve临床试验
Neurol Clin Pract. 2021 Oct;11(5):e722-e726. doi: 10.1212/CPJ.0000000000001074.
6
Social Media and Clinical Trials in Pediatric Disease: Musings From the Bench.社交媒体与儿科疾病临床试验:实验室的思考
Front Genet. 2021 Oct 4;12:734691. doi: 10.3389/fgene.2021.734691. eCollection 2021.
7
Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research.利益相关者对罕见病治疗相关临床研究的看法:治疗误解和研究的价值。
Orphanet J Rare Dis. 2021 Jan 12;16(1):26. doi: 10.1186/s13023-020-01624-0.
8
Patient's thoughts and expectations about centres of expertise for PKU.患者对苯丙酮尿症专业治疗中心的想法和期望。
Orphanet J Rare Dis. 2021 Jan 6;16(1):2. doi: 10.1186/s13023-020-01647-7.
9
Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.多种硫酸酯酶缺乏症:一种由翻译后修饰缺陷引起的包含黏多糖贮积症、鞘脂贮积症等疾病的综合征。
Int J Mol Sci. 2020 May 13;21(10):3448. doi: 10.3390/ijms21103448.
10
Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.一类新药创新靶点的临床试验、进展速度区分特征及快速性规则
Brief Bioinform. 2020 Mar 23;21(2):649-662. doi: 10.1093/bib/bby130.
通过佩普劳人际关系理论改善研究对象的招募、留存率及参与度。
Nurs Sci Q. 2011 Apr;24(2):146-51. doi: 10.1177/0894318411399454.
4
Transition of young adults with phenylketonuria from pediatric to adult care.苯丙酮尿症青少年患者从儿科向成人医疗的过渡。
J Inherit Metab Dis. 2011 Jun;34(3):701-9. doi: 10.1007/s10545-011-9284-x. Epub 2011 Feb 9.
5
Strategies for increasing recruitment to randomised controlled trials: systematic review.增加随机对照试验招募的策略:系统评价。
PLoS Med. 2010 Nov 9;7(11):e1000368. doi: 10.1371/journal.pmed.1000368.
6
The reality of dietary compliance in the management of phenylketonuria.苯丙酮尿症管理中饮食依从性的现实情况。
J Inherit Metab Dis. 2010 Dec;33(6):665-70. doi: 10.1007/s10545-010-9073-y. Epub 2010 Apr 7.
7
Psychiatric symptoms and disorders in phenylketonuria.苯丙酮尿症患者的精神症状和障碍。
Mol Genet Metab. 2010;99 Suppl 1:S59-63. doi: 10.1016/j.ymgme.2009.10.182.
8
PKU adults and their return to diet: predicting diet continuation and maintenance.苯丙酮尿症成年人及其恢复饮食:预测饮食的持续和维持情况。
J Inherit Metab Dis. 2001 Aug;24(4):515-6. doi: 10.1023/a:1010546000617.